Symptomatic coronary artery disease affects an estimated 6.4 million people in the United States, with roughly 400,000 new cases diagnosed each year. Despite appropriate medicinal therapy and invasive procedures such as angioplasty and heart bypass surgery, refractory anginapectoris affects an estimated 300,000 to 900,000 people in the United States (RAP). Every year, between 25,000 and 75,000 new instances of RAP are discovered. Enhanced External Counter Pulsation (EECP) therapy involves rapid, successive compression of the lower limbs during diastole, followed by simultaneous de compression during systole, as determined by an ECG. These actions create hemodynamic effects comparable to those of an intra-aortic balloon pump, but EECP therapy also enhances venous return, unlike an intra-aortic balloon pump. The Multi-center Study of Enhanced External Counter Pulsation (MUST-EECP) is the first multi-center, prospective, randomised controlled experiment that looked at the effects of EECP on patients with stable angina. In the Research on Enhanced External Counter Pulsation Therapy in Coronary Artery Disease (RECC) trial, individuals with stable angina who received EECP in addition to appropriate medical therapy saw an improvement in myocardial ischemia and prognosis. In addition, EECP has been demonstrated to cause coronary collateral development. Although EECP is a relatively safe and well-developed treatment, a safety assessment is required for high-risk and elderly patients before administration to rule out contraindications and minimise treatment-related hazards. The counter pulsation approach, which has been studied for nearly half a century, is regarded a safe, very helpful, low-cost, noninvasive treatment for these angina patients, as well as heart failure patients. Recent research suggests that enhanced external counter pulsation (EECP) therapy may improve symptoms and reduce long-term morbidity through multiple mechanisms, including improved endothelial function, collateralization, ventricular function, oxygen consumption (VO2), atherosclerosis regression, and peripheral training effects similar to exercise.
Author(s) Details
Najah R. Hadi
Faculty of Medicine, University of Kufa, Iraq.
Alzahra Teaching Hospital, Alnajaf Health Directorate, Iraq.
Jan Fedacko
Pavol Jozef Šafárik University, Košice Faculty of Medicine, Slovakia.
View Book:- https://stm.bookpi.org/EECCPFD/article/view/5084
No comments:
Post a Comment